Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pelacarsen Safety and PK Study in Healthy Japanese Participants
NCT05337878Phase 1Completed
- Sponsor
- Ionis Pharmaceuticals
- Start
- Oct 2018
- Primary completion
- Dec 2019
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of pelacarsen in Hyperlipoproteinemia a (6 arms), sponsored by Ionis Pharmaceuticals. Primary endpoint: Percentage of Participants With Clinically Significant Changes From Baseline in Clinical Laboratory Evaluation Parameters. Started Oct 2018; status: completed.
02
Drugs
pelacarsen
03
Conditions
Hyperlipoproteinemia a
Beyond the preview
Go deeper on NCT05337878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05337878.